Since 2016, Eli Lilly's revenue grew 60% but income grew by 91%. Investor sentiment for the next line of drugs propelled the stock price significantly.
Eli Lilly's stock was valued at 13 times earnings in 2016 but now trades at 125 times earnings, questioning if future revenues will justify the expensive valuation.
Collection
[
|
...
]